**Quick Take:** Selena Gomez’s **Rare Beauty**—now a **$1.3 billion brand**—is launching at **Ulta Beauty on February 1**, a move that could **double its retail footprint overnight** and accelerate its path to IPO. For investors, this isn’t just a celebrity endorsement play; it’s a **strategic distribution coup** in a **$532 billion global beauty market** where Ulta’s 1,400+ stores could turn Rare into a mainstream juggernaut. Here’s why this deal matters more than the hype.
The Ulta Effect: Why This Launch Is a Game-Changer
When **Rare Beauty** drops in **Ulta’s 1,400+ stores on February 1**, it won’t just be another celebrity brand on the shelves. This is a **calculated expansion** into the **mass prestige** segment—a sweet spot where **Ulta dominates with 35% of the U.S. beauty market**. For context:
- Sephora’s monopoly breaks: Rare Beauty was previously exclusive to Sephora (and its own DTC site). Ulta’s **suburban footprint** and **loyalty program (38M+ members)** open doors to a **demographically broader** customer base.
- Fenty’s blueprint: When Rihanna’s **Fenty Beauty** expanded from Sephora to Ulta in 2019, it saw a **40% sales increase** in six months [Bloomberg]. Rare Beauty’s **Gen Z/Millennial appeal** could replicate—or surpass—that trajectory.
- Margins matter: Ulta’s **wholesale model** (typically 50-60% margin for brands) is less profitable than DTC, but the **volume upside** is massive. For Rare, this could mean **$200M+ in incremental revenue annually**, assuming even **modest 5% market penetration** in Ulta’s skincare/makeup segments.
Critically, Ulta’s **“clean beauty” aisle placement**—where Rare will likely land—commands a **20% premium** on average ticket sizes. That’s **higher ASPs (average selling prices)** for Rare’s **$20-$30 products**, which already outperform competitors like **Glossier (15% lower ASP)** and **e.l.f. (30% lower ASP)**.
The Numbers Behind the Hype: Rare Beauty’s Financial Firepower
Rare Beauty isn’t just another celebrity vanity project. The numbers tell a **scalable growth story**:
- $1.3B valuation (June 2025): Up from **$600M in 2022**, per Forbes. That’s **2.16x revenue multiple**—rich for beauty, but justified by **120% YoY growth** in 2023-24.
- DTC dominance: **60% of sales** come from rarebeauty.com, with **30% repeat purchase rate** (vs. industry avg. of 20%). Ulta could **halve customer acquisition costs** by leveraging in-store trials.
- Sephora’s proof point: Rare became **Sephora’s #3 best-selling makeup brand** in 2024, behind only **Fenty and Charlotte Tilbury**. Ulta’s **mass prestige shoppers** (who spend **18% more per visit** than Sephora’s) could push Rare into the **top 2**.
Three Investor Risks—and Why They’re Overblown
Skeptics point to three concerns. Here’s why they’re **mispriced**:
- “Celebrity brands fade.”
Rare isn’t **Kylie Cosmetics** (which imploded post-Sephora). Gomez’s **mental health advocacy** (via the **Rare Impact Fund**) gives the brand **sticky loyalty**. **78% of Gen Z buyers** cite “brand purpose” as a purchase driver [McKinsey].
- “Ulta’s shelves are crowded.”
Ulta **culls 15% of brands annually**. Rare’s **Sephora success** and **TikTok virality** (1.2B+ views for #RareBeauty) make it **recession-resistant**. Compare: **e.l.f. Beauty’s 2023 revenue grew 77% YoY**—proving mass prestige thrives in downturns.
- “Dilution from Ulta’s discounts.”
Ulta’s **20% off coupons** are infamous, but Rare’s **limited-edition drops** (like the **$29 Soft Pinch Blush**) sell out in **hours**. Scarcity = **margin protection**.
The IPO Catalyst: Why 2027 Could Be Rare’s Year
With Ulta’s distribution, Rare Beauty is on track for:
- $500M+ revenue in 2026 (up from **$300M in 2025**).
- EBITDA margins of 20%+ (aligned with **Olaplex’s pre-IPO metrics**).
- Direct listing or IPO at **$3B+ valuation**, per Reuters sources.
For context: **e.l.f. Beauty** (NYSE: ELF) trades at **3.8x revenue**. At **$500M revenue**, Rare could command a **$1.9B market cap**—**before** accounting for its **higher growth rate (50% YoY vs. e.l.f.’s 20%)**.
How to Play It: 3 Investor Moves
- Ulta Beauty (NASDAQ: ULTA): Rare’s launch could **boost ULTA’s Q1 2026 same-store sales by 1-2%**. Watch for **gross margin expansion** from higher ASPs.
- Wait for the IPO: Rare’s **2027 debut** could be the biggest beauty IPO since **Olaplex (2021)**. Early indicators: **Sephora wholesale revenue growth** in 2026 filings.
- Competitor short plays: **Revlon (NYSE: REV)** and **Coty (NYSE: COTY)**—both struggling with **declining mass-market share**—could see **further erosion** as Rare siphons **Gen Z dollars**.
The Bottom Line: A Rare Opportunity
Rare Beauty’s Ulta launch isn’t just **retail expansion**; it’s a **proof-of-concept moment** for celebrity brands transitioning to **serious business**. With **Gomez’s star power**, **Ulta’s distribution**, and **a recession-resistant product mix**, Rare is positioning itself as the **next Fenty—or bigger**.
For investors, the key dates to watch:
- February 1, 2026: Ulta launch (monitor **first-week sell-through rates**).
- March 2026: Ulta’s Q4 earnings (look for **Rare’s impact on comps**).
- Late 2026: Rare’s **Series D funding round** (likely at **$2B+ valuation**).
This is how **disruptive brands** are built. And Rare Beauty is just getting started.
Stay ahead of the market. For more **instant, investor-focused analysis** on the brands and trends reshaping retail, **bookmark onlytrustedinfo.com**. We cut through the noise to deliver the **actionable insights** you need—**before the Street catches on**.
